Search

The article presents the requirements of the EU EPBD (Energy Performance of Buildings Directive) for counting the carbon footprint (especially in Scope 3) and including it in construction projects from 2030. The obligation to count the carbon footprint will burden mainly designers, who are increasingly using BIM (Building Information Modelling) in the design process. Performing analysis and calculation of the carbon footprint in BIM models is hampered by the lack of non-graphical information on the subject in library components. The paper explains the concept of CO2 in 3 scope, also discusses currently available tools for counting the carbon footprint, and examines how many components available on the Internet already contain non-graphical information on emissions, as well as ideas for implementing this directive. The advantages and disadvantages of these approaches were presented from the perspective of various stakeholders in the planning and investment and construction processes. The aim of the paper was to present possible solutions, ensuring compliance with the EU directive by proposing specific techniques, enabling the calculation of the Scope 3 carbon footprint, using BIM. In addition to a review of existing ideas, an authorial proposal for a national repository of carbon footprint information taking into account all stakeholders was presented. [ABSTRACT FROM AUTHOR]

The group of innovative ingredients in cosmetic preparations includes bio-ferments (Bs), which are characterized by high bioactivity and biocompatibility, and one of the plants rich in bioactive compounds that has a beneficial effect on the skin and the body is Silybum marianum. Bio-ferments obtained from this plant are becoming increasingly useful as active ingredients in cosmetics. In the present study, four different bio-ferments were obtained by fermentation of pomace (B-P), extract (B-E), oil (B-O), and seeds (B-S) of milk thistle. Their biodegradability (%B), total polyphenols content (Folin–Ciocalteu method), and antimicrobial, antioxidant (DPPH, ABTS, and FRAP methods), chelating (Fe2+ ions), and reduction (Cu2+ and Fe3+ ions) properties, as well as the acidity, were evaluated. The contact angle using the sessile drop method was assessed to investigate bio-ferments' impact on skin wettability. Finally, the content of selected phenolic acids in the Bs was evaluated using the HPLC method, while the lactic acid (LA) content was assessed using the GC-MS method. All bio-ferments were characterized by high polyphenols content (13.56 ± 0.10–15.28 ± 0.12 mmol GA/L B), chelating (0.08 ± 0.01–0.17 ± 0.01 mmol Fe2+/L B) and antioxidant activity (DPPH method, 2.41 ± 0.01–3.53 ± 0.01 mmol Tx/L B), and reducing Cu2+ and Fe3+ ions. Gallic acid, protocatechuic acid, caffeic acid, neochlorogenic acid, coumaric acid, and LA were identified in Bs. The most increased antibacterial activity for B-P was observed for a strain of Staphylococcus aureus (MIC = 250 μL/mL) and Pseudomonas aeruginosa (MIC = 250 μL/mL). Simultaneously, B-S demonstrated the highest inhibitory effects against Escherichia coli (MIC = 125 μL/mL), emphasizing the varied antimicrobial profiles of these bio-ferments against different bacterial strains. Research on aerobic biodegradation demonstrated a high level of degradation (%B = 60 ± 1–65 ± 3), and all Bs were categorized as readily degradable according to the OECD classification. [ABSTRACT FROM AUTHOR]

Urinary tract infections (UTIs) are among the most common bacterial infections affecting millions worldwide. The increasing emergence of antibiotic-resistant bacteria has become a serious concern in managing UTIs. Therefore, there is a growing interest in using bacteriophages as an alternative or adjunct therapy for UTIs. Bacteriophages are viruses that infect and kill bacteria, making them a promising tool for treating UTIs caused by antibiotic-resistant bacteria. This article provides a quick outlook on using bacteriophages to treat UTIs. We summarize the current understanding of the biology of bacteriophages, the challenges associated with developing phage-based therapies, and the promising results of several case reports and clinical trials. We also highlight the potential of phage therapy as a valuable tool in the fight against antibiotic-resistant UTIs. This quick outlook on a bacteriophage-based approach for treating UTIs offers a timely and informative summary of the current research in this field. [ABSTRACT FROM AUTHOR]